These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29998524)

  • 1. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
    Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
    Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
    Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W; Hébert J; Hanzlikova J; Staubach-Renz P; Martinez-Saguer I; Magerl M; Aygören-Pürsün E; Farkas H; Reshef A; Kivity S; Neri S; Crisan I; Caballero T; Baeza ML; Hernandez MD; Li H; Lumry W; Bernstein JA; Hussain I; Anderson J; Schwartz LB; Jacobs J; Manning M; Levy D; Riedl M; Christiansen S; Feuersenger H; Pragst I; Mycroft S; Pawaskar D; Jacobs I;
    J Allergy Clin Immunol Pract; 2019; 7(6):1793-1802.e2. PubMed ID: 30772477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
    Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
    J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
    Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
    Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema.
    Zhang Y; Tortorici MA; Pawaskar D; Pragst I; Machnig T; Hutmacher M; Zuraw B; Cicardi M; Craig T; Longhurst H; Sidhu J
    CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):158-165. PubMed ID: 29316335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study.
    Martinez-Saguer I; Cicardi M; Suffritti C; Rusicke E; Aygören-Pürsün E; Stoll H; Rossmanith T; Feussner A; Kalina U; Kreuz W
    Transfusion; 2014 Jun; 54(6):1552-61. PubMed ID: 24266596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
    Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
    Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
    Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
    Riedl M
    Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
    Li HH; Mycroft S; Christiansen S; Wood DN; Feuersenger H; Pawaskar D; Jacobs I
    Allergy Asthma Proc; 2018 Sep; 39(5):365-370. PubMed ID: 30107868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks.
    Grant JA; White MV; Li HH; Fitts D; Kalfus IN; Uknis ME; Lumry WR
    Allergy Asthma Proc; 2012; 33(4):348-53. PubMed ID: 22856635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
    Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
    Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema.
    Henry Li H; Riedl M; Kashkin J
    Clin Rev Allergy Immunol; 2019 Apr; 56(2):207-218. PubMed ID: 29909591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
    Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
    Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks.
    Bernstein JA; Li HH; Craig TJ; Manning ME; Lawo JP; Machnig T; Krishnarajah G; Fridman M
    Allergy Asthma Clin Immunol; 2019; 15():13. PubMed ID: 30899278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of recombinant human C1 esterase inhibitor in children with hereditary angioedema.
    Hayes S; Farrell C; Relan A; Anderson J
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):707-712. PubMed ID: 33609769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for the long-term prevention of hereditary angioedema attacks.
    Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
    Levy D; Caballero T; Hussain I; Reshef A; Anderson J; Baker J; Schwartz LB; Cicardi M; Prusty S; Feuersenger H; Pragst I; Manning ME
    Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):136-141. PubMed ID: 32953229
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study.
    Martinez-Saguer I; Rusicke E; Aygören-Pürsün E; von Hentig N; Klingebiel T; Kreuz W
    Transfusion; 2010 Feb; 50(2):354-60. PubMed ID: 19788511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.